Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
565 studies found for:    PAH
Show Display Options
RSS Create an RSS feed from your search for:
PAH
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Active, not recruiting Training With Whole Body Vibration Device in Patients With PAH
Condition: Pulmonary Artery Hypertension
Intervention: Device: Exercise Group Galileo PAH
2 Completed Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
Conditions: Pulmonary Arterial Hypertension;   Pulmonary Hypertension
Interventions: Drug: Nitric Oxide;   Other: Placebo
3 Active, not recruiting Prevalence of Pulmonary Hypertension (PAH) in Patients With Thalassemia
Conditions: Thalassemia Major;   Thalassemia Intermedia;   Pulmonary Arterial Hypertension
Intervention: Other: Physician standard-of-care according to ESC/ERS Guidelines
4 Completed BEET PAH: a Study to Assess the Effects of Beetroot Juice in Patients With Pulmonary Arterial Hypertension
Condition: Pulmonary Arterial Hypertension
Intervention: Dietary Supplement: Beetroot juice
5 Active, not recruiting Pulmonary Artery Denervation for Treatment of Pulmonary Arterial Hypertension
Condition: Life Change Events
Interventions: Procedure: Pulmonary Arterial Denervation (PADN);   Drug: Sildenafil;   Drug: Bosentan;   Drug: Prostacyclin
6 Active, not recruiting Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Condition: Pulmonary Arterial Hypertension
Intervention:
7 Terminated Obstructive Sleep Apnea in Pulmonary Arterial Hypertension (OSA in PAH)
Conditions: Pulmonary Arterial Hypertension;   Obstructive Sleep Apnea
Intervention:
8 Recruiting Hormonal, Metabolic, and Signaling Interactions in PAH
Conditions: Idiopathic Pulmonary Arterial Hypertension;   Heritable Pulmonary Arterial Hypertension;   Scleroderma Associated Pulmonary Arterial Hypertension;   Appetite Suppressant Associate PAH
Intervention:
9 Completed PSA-Activated PSA-PAH1 for Locally Recurrent Prostate Cancer
Condition: Prostate Cancer
Intervention: Drug: PSA-Activated PSA-PAH1
10 Recruiting Prospective, Non-interventional, Multi-center, Post-authorization Safety Study of Riociguat for Pulmonary Arterial Hypertension (PAH)
Condition: Hypertension, Pulmonary
Intervention: Drug: Riociguat (ADEMPAS, BAY63-2521)
11 Enrolling by invitation Ventricular Reversed Remodeling After LTX in PAH Patients
Condition: Pulmonary Arterial Hypertension
Intervention:
12 Completed
Has Results
FK506 (Tacrolimus) in Pulmonary Arterial Hypertension
Condition: Pulmonary Arterial Hypertension
Interventions: Drug: Placebo;   Drug: FK506 level < 2 ng/ml;   Drug: FK506 level 2-3 ng/ml;   Drug: FK506 level 3-5 ng/ml
13 Recruiting Dysregulation of Lipid Metabolism and Right Ventricular Function in PAH
Condition: Pulmonary Arterial Hypertension
Interventions: Procedure: Blood Sampling;   Other: Cardiac MRI
14 Completed Biomarkers in the Diagnosis and Assessment of Pulmonary Arterial Hypertension (PAH)
Condition: Pulmonary Arterial Hypertension
Intervention: Other: Blood draw
15 Active, not recruiting DelIVery for Pulmonary Arterial Hypertension (PAH)
Condition: Pulmonary Arterial Hypertension
Intervention: Device: Model 10642 Implantable Intravascular Catheter
16 Completed Dose-response Study of the Safety and Efficacy of Beraprost Sodium Modified Release (BPS-MR) in Patients With Pulmonary Arterial Hypertension (PAH)
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Beraprost Sodium Modified Release
17 Completed An Open-Label Extension of BPS-MR-PAH-201 in Pulmonary Arterial Hypertension (PAH) Patients
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Beraprost Sodium Modified Release
18 Recruiting [18F]FES PET/CT in PAH
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: [18F] FES
19 Not yet recruiting Long-term Extension Study of the Safety and Pharmacokinetics of QCC374 in PAH Patients
Condition: Pulmonary Arterial Hypertension (PAH)
Intervention: Drug: QCC374
20 Not yet recruiting Estrogen Receptor Antagonist in Patients With Pulmonary Arterial Hypertension
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Fulvestrant

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.